Octagam (Human Normal Immunoglobulin)

The pooled IgG antibodies in Octagam bind to a broad spectrum of antigens, neutralize pathogens, and interact with Fc receptors on immune cells, which helps restore normal antibody levels and modulates immune system activity, reducing harmful inflammation.

The dose of Octagam is individualized by the prescribing clinician based on the patient’s condition, weight, and clinical response. Healthcare providers calculate the appropriate volume and infusion rate for each patient.

Octagam is classified as a category C product; it should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding, and a risk‑benefit assessment should be performed by the treating physician.

To order Octagam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Octagam is comparable to other IVIG preparations in its composition of pooled human IgG, but differences may exist in manufacturing processes, stabilizers, and approved indications. Clinicians consider factors such as infusion tolerability, concentration, and supply reliability when selecting an IVIG product.

Octagam must be stored refrigerated at 2‑8°C, protected from light, and should never be frozen or shaken. Before use, the vial should be inspected for particulate matter and allowed to reach room temperature if required by the administration protocol.

Octagam is given as an intravenous infusion under medical supervision. The infusion rate is started slowly and may be increased based on patient tolerance, with vital signs monitored throughout the procedure.

Serious risks include anaphylactic reactions, acute hemolytic anemia, thromboembolic events, renal impairment, and aseptic meningitis. Prompt recognition and management of these events are essential during and after infusion.

Octagam is contraindicated in patients with a known severe IgA deficiency who have anti‑IgA antibodies, a history of severe anaphylactic reactions to immunoglobulin products, or uncontrolled hyperviscosity. Clinicians should evaluate each patient’s medical history before initiating therapy.